Practical Issues in the Management of Hypersensitivity Reactions: Sulfonamides

Approximately 3% of the general population and 60% of patients with human immunodeficiency virus (HIV) infection have adverse reactions when treated with sulfonamide antimicrobials. The most common clinical manifestations of sulfonamide hypersensitivity are fever and a maculopapular rash 7 to 14 days after initiating therapy, though a variety of more severe manifestations may occur. The sulfonamide chemical moiety is present in many medications that are not antimicrobials, and fortunately hypersensitivity reactions to these medications are less common. The immunogenicity of sulfonamide antimicrobials may be due to the presence of an arylamine group at the N4 position of the sulfonamide molecule. No diagnostic tests are available to confirm sulfonamide hypersensitivity, and while avoidance of the drug is generally appropriate when a previous hypersensitivity reaction is suspected, desensitization protocols are available for use in HIV patients in whom Pneumocystis carinii pneumonia prophylaxis or treatment is indicated.

[1]  R. Patterson,et al.  The outcome of Stevens-Johnson syndrome treated with corticosteroids. , 1995, Allergy proceedings : the official journal of regional and state allergy societies.

[2]  R. Patterson,et al.  Management of drug allergy in patients with acquired immunodeficiency syndrome. , 1987, The Journal of allergy and clinical immunology.

[3]  J. Anderson,et al.  Allergic reactions to drugs and biologic agents. , 1987, JAMA.

[4]  R. Gruchalla,et al.  Detection of human IgE to sulfamethoxazole by skin testing with sulfamethoxazoyl-poly-L-tyrosine. , 1991, The Journal of allergy and clinical immunology.

[5]  R. Gruchalla,et al.  Immunochemical analysis of sulfonamide drug allergy: identification of sulfamethoxazole-substituted human serum proteins. , 1994, The Journal of allergy and clinical immunology.

[6]  R. Patterson,et al.  Drug allergy and protocols for management of drug allergies. , 1995, Allergy proceedings : the official journal of regional and state allergy societies.

[7]  D. Skiest,et al.  Sulfonamide-induced reactions in desensitized patients with AIDS--the role of covalent protein haptenation by sulfamethoxazole. , 1998, The Journal of allergy and clinical immunology.

[8]  C. González‐Herrada,et al.  Treatment of toxic epidermal necrolysis with cyclosporin A. , 2000, The Journal of trauma.

[9]  J. Koski.  Desensitization to sulphasalazine in patients with arthritis. , 1993, Clinical and Experimental Rheumatology.

[10]  D. Grant,et al.  Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. , 1986, Annals of internal medicine.

[11]  H. Merk,et al.  Metabolites and allergic drug reactions. , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[12]  D. Cooper,et al.  In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV , 1993, Clinical and experimental immunology.

[13]  J. Rich,et al.  Trimethoprim/sulfamethoxazole incremental dose regimen in human immunodeficiency virus-infected persons. , 1997, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[14]  M. Fischl,et al.  Rapid oral desensitization for sulfonamides in patients with the acquired immunodeficiency syndrome. , 1995, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[15]  L. Hughes-Davies,et al.  Severe adverse cutaneous reactions to drugs. , 1995, The New England journal of medicine.

[16]  J. Roujeau.  The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. , 1994, The Journal of investigative dermatology.

[17]  H. S. Earl,et al.  Studies of human IgE to a sulfonamide determinant. , 1987, The Journal of allergy and clinical immunology.

[18]  T. J. Sullivan.  Cross-reactions among furosemide, hydrochlorothiazide, and sulfonamides. , 1991, JAMA.

[19]  D. Spelman,et al.  Successful desensitization of two patients who previously developed Stevens-Johnson syndrome while receiving trimethoprim-sulfamethoxazole. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  D. Chaplin,et al.  Anaphylaxis to intravenous furosemide. , 1987, The Journal of allergy and clinical immunology.

[21]  B. Baldo,et al.  Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethoxazole. , 1988, Molecular immunology.

[22]  S P Spielberg,et al.  Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. , 1996, Adverse drug reactions and toxicological reviews.

[23]  W. Mccloskey,et al.  Glutathione in Hypersensitivity to Trimethoprim/Sulfamethoxazole in Patients with HIV Infection , 1998, The Annals of pharmacotherapy.

[24]  D. Cooper,et al.  Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. , 1993, The Journal of infectious diseases.

[25]  M. Bouvy,et al.  Applied Therapeutics: The Clinical Use of Drugs. , 1997, Pharmacy World and Science.

[26]  J. Roujeau,et al.  Genetic susceptibility to toxic epidermal necrolysis. , 1987, Archives of dermatology.

[27]  J. Lefkowith.  Cyclooxygenase-2 specificity and its clinical implications. , 1999, The American journal of medicine.